Catalog No.
PHB90001
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human C5 (Thr678-Arg751).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
CPAMD4,C5,C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4,Complement C5
Purification
Purified by antigen affinity column.
Accession
P01031
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Epitope-guided selection of CXCR4-targeting antibodies using AlphaFold3 for GPCR modulation and cancer therapy., PMID:40520880
Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance., PMID:40515788
Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica., PMID:40506785
[Diagnosis, treatment, and genetic analysis of five cases of primary atypical hemolytic uremic syndrome]., PMID:40484823
Aptamers as therapeutic targets: prospects and progress in the treatment of cancers., PMID:40479828
Monoclonal antibodies targeting Candida disrupt biofilms and inhibit growth across global clinical isolates., PMID:40458186
Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis., PMID:40453104
A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS)., PMID:40448185
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors., PMID:40447351
Isolation and Characterization of E8 Monoclonal Antibodies from Donors Vaccinated with Recombinant Vaccinia Vaccine with Efficient Neutralization of Authentic Monkeypox Virus., PMID:40432083
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis., PMID:40422242
Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the Literature., PMID:40414204
Aggressive and Refractory Attack of AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab: A Case Report., PMID:40400837
Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI., PMID:40388640
PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database., PMID:40375186
Therapeutic targeting of alternative pathway and C5 but not C5a protects from disease development in a preclinical model of autoimmune blistering dermatosis., PMID:40370446
Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience., PMID:40366475
Advancements in Complement Inhibition for PNH and Primary Complement Mediated Thrombotic Microangiopathy., PMID:40354320
Eculizumab in severe pediatric STEC-HUS and its impact on neurological prognosis-a systematic review and meta-analysis., PMID:40341411
Thrombospondin-1 inhibits alternative complement pathway activation in antineutrophil cytoplasmic antibody-associated vasculitis., PMID:40338657
Interferon Causes Endothelial Injury in Humans., PMID:40326264
Real-World Case Series of Ravulizumab Use in Patients with Myasthenia Gravis in Romania., PMID:40309792
Seroprevalence of anti-influenza antibodies in humans and characterization of seasonal influenza viruses isolated in Russia during the 2023-2024 flu season., PMID:40307541
Complement dysregulation at lymphatics., PMID:40300720
Comparative Forced Degradation Study of Anticomplement C5 Biosimilar and Originator Monoclonal Antibodies., PMID:40284014
Discovery of PD-L1 Peptide Inhibitors from Ascidian Enzymatic Hydrolysates by Affinity Ultrafiltration Coupled to NanoLC-MS/MS., PMID:40278258
Activated blood-derived human primary T cells support replication of HAdV C5 and virus transmission to polarized human primary epithelial cells., PMID:40265914
The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment., PMID:40257298
A new treatment for canine B-cell lymphoma based on a recombinant single-domain antibody immunotoxin derived from Pseudomonas aeruginosa exotoxin A., PMID:40256602
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension., PMID:40241307
[Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria]., PMID:40237732
Complement C3 Deficiency Enhances Renal Leptospiral Load and Inflammation While Impairing T Cell Differentiation During Chronic Leptospira interrogans Infection., PMID:40236016
Mechanism and regulation of the complement activity in kidney xenotransplantation., PMID:40233672
IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia., PMID:40229904
Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohort., PMID:40224677
Complement updates in optic neuritis., PMID:40206291
A Potential Link Between HLA-DRB1/DQB1 Alleles and Response to Treatment in Rheumatoid Arthritis Patients., PMID:40195278
Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old., PMID:40188565
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States., PMID:40163049
GRP78 Nanobody-Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy., PMID:40135833
Crovalimab: a new era in paroxysmal nocturnal hemoglobinuria management., PMID:40110253
Development of Anti-CEA CH2 Domain-Deleted Antibody (M5A∆CH2) for the PET Imaging of Colorectal Cancer., PMID:40085171
A Critical Oversight in Immunology Research: The Prevalence of Complement Deficiencies in Mouse Models., PMID:40071687
Use of complement C5-inhibitor eculizumab in patients with infection-associated hemolytic uremic syndrome - a case-series report., PMID:40065282
Prophylactic use of eculizumab for ABO-blood type incompatible kidney transplantation with extremely high ABO-blood type antibody titer: A two case report., PMID:40024311
Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy., PMID:40023814
Real-world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study., PMID:39985320
Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders., PMID:39983521
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome., PMID:39982653
IL-6 mediates defense against influenza virus by promoting protective antibody responses but not innate inflammation., PMID:39978550
For research use only. Not for human or drug use.
